To unlock the vast potential hidden within our proteome & make better drugs
We are SyntheX
SyntheX was started to address gaps in existing drug discovery technologies. As geneticists identify high-potential drug targets, many of these targets are inaccessible to traditional pharmacological intervention due to limitations of existing technologies and are consequently deprioritized.
We invented the ToRFLEx platform to overcome these limitations. By integrating target proteins into our engineered cells, we can screen for functional compounds that can unlock complex mechanisms of action for the best targets of interest that geneticists identify. We are particularly focused on two main mechanisms: protein-protein interaction inhibitors and proximity inducers to achieve targeted protein degradation.
Our process is to identify the best targets and hypothesize the ideal pharmacological intervention to maximize patient benefit and minimize clinical resistance. Then we configure ToRFLEx to screen for compounds that achieve the desired drug mechanism of action from a first pass.
Using this first-in-class approach, we’ve generated a differentiated internal oncology pipeline for genetically validated & previously inaccessible targets and formed collaborations with external partners to expand the reach of our technology.
Expanding the horizons of drug discovery
SyntheX prides itself on a science-first ethos, driving innovation and tackling complex challenges. By broadening the drug discovery toolkit and targeting elusive proteins, we are committed to overcoming technological bottlenecks that prevent the optimal drugs from reaching patients.
Leadership Team
Scientific Advisory Board
Strategic Advisors
Maria Soloveychik, PhD
- 18+ years in molecular biology and biochemistry, with a focus on drug discovery and genetic engineering
- Contributed to 9 published PDB structures, discovered novel epigenetic signaling pathways
- Spearheaded venture fundraising, business development, company building & scaling from ideation stage
Charly Chahwan
- 25+ years in molecular biology and genetics focusing on cell cycle, DNA repair, genomic stability
- Secured multiple governmental grants, over 20 peer-reviewed publications
- Pioneered SyntheX’s ToRFLEx platform, advancing novel compounds towards the clinic
Tri Luong, MBA
- 15+ years in finance and operations, healthcare and tech industry focus
- Managed $2.6B portfolio, led IPO execution, raised $1.6B debt, closed $650M deals
- Built analytics teams, improved KPI visibility, created incentive programs for growth
Mike Johnson, PhD
- 30+ years in small molecule drug design and development across various therapeutic areas
- Led teams to achieve IND and FIH milestones, advancing drug discovery R&D
- Expertise in biotech start-ups, large pharma, and CRO environments
Leonard Post
41+ years in pharma leadership, multiple approved medicines and exits
Andrew Perlman
30+ years in biotech, raised $100M+, led IPO on NYSE, $350M market cap
Tomi Sawyer
40+ years in biotech, multiple approved medicines, 640+ publications
Michelle Arkin
25+ years in small molecule drug discovery, two biotechs in clinical trials
Ning Zheng
33+ years in structural biology and leader in protein degradation research
Robert Williamson
30+ years in biotechnology and corporate strategy
Heather Berger
20+ years in research, biotech corporate dev., business ops, and venture capital
Our Partners
Investors
Community
Partners
